Abstract
Objective Thrombospondin 2 (THBS2) acts as oncogenic or tumor suppressive gene in diverse cancers. Here we studied the prognostic and immunological role of THBS2 in colorectal cancer (CRC) using bioinformatic analysis. Methods The genetic and protein expression of THBS2 in CRC were explored across several databases, including ONCOMINE, GEPIA2, TIMER 2.0, UALCAN and HPA databases. Correlation between THBS2 expression and clinical features in CRC was assessed using UALCAN tool. Prognostic analysis was performed using GEPIA2 and PrognoScan. Immune infiltration correlation with THBS2 in CRC was investigated with TIMER 2.0 and TISIDB. THBS2 binding and correlated genes were analyzed using String, GEPIA2, and TIMER 2.0. Results THBS2 was significantly higher in CRC across multiple databases. Age and histological subtype were correlated with THBS2 level. High THBS2 expression correlated with short overall and disease-free survival. THBS2 expression was positively correlated with immune infiltrates in CRC. Moreover, extracellular matrix structural constituent and organization, PI3K-Akt pathway, were involved in the functional mechanisms of THBS2. Conclusions THBS2 correlates with poor prognosis and immune infiltration in CRC. THBS2 may act as a prognostic and immunological biomarker for CRC.
Highlights
Colorectal cancer (CRC) is one of the most frequent lethal malignant cancers of the digestive tract worldwide [1]
Thrombospondin 2 (THBS2) is recognized as an Extracellular matrix protein-protein interaction (PPI) (ECM)-modifying enzyme and functions as a suppressor of tumor growth and angiogenesis by interacting with matrix serine proteases and MMPs in numerous cancers [16]
We comprehensively examined the genetic and protein expression, prognostic, and immunological role of THBS2 in CRC based on datasets from TCGA, CPTAC and GEO databases
Summary
Colorectal cancer (CRC) is one of the most frequent lethal malignant cancers of the digestive tract worldwide [1]. Metastatic CRC usually develops from benign tumor over time, and the prevalence of CRC is still increasing. Patients with CRC are diagnosed at advanced stages, remarkable advances in the diagnosis and treatment of CRC have achieved. The 5-year overall survival (OS) rate of metastatic CRC is less than 15% [2]. Diagnosis at early stage could increase the 5-year survival rate. Tumor microenvironment (TME) plays critical roles in tumor development involving the interaction between cancer cells, tumor infiltrating immune cells, and their supporting cells.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
